Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 120561775 | 12056177 | 5 | F | 20151217 | 20160830 | 20160210 | 20160907 | EXP | US-BIOGEN-2016BI00182725 | BIOGEN | 64.28 | YR | M | Y | 0.00000 | 20160907 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 120561775 | 12056177 | 1 | PS | TYSABRI | NATALIZUMAB | 1 | Unknown | 125104 | UNKNOWN | ||||||||||
| 120561775 | 12056177 | 2 | SS | TYSABRI | NATALIZUMAB | 1 | Unknown | 125104 | UNKNOWN |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 120561775 | 12056177 | 1 | Multiple sclerosis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 120561775 | 12056177 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 120561775 | 12056177 | Death | |
| 120561775 | 12056177 | Hypersensitivity | |
| 120561775 | 12056177 | Malaise | |
| 120561775 | 12056177 | Pneumonia | |
| 120561775 | 12056177 | Speech disorder | |
| 120561775 | 12056177 | Tremor |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 120561775 | 12056177 | 1 | 20150825 | 0 | ||
| 120561775 | 12056177 | 2 | 20151217 | 0 |